促红细胞生成素治疗糖尿病视网膜病变的研究进展  

Research progress of erythropoietin in the treatment of diabetic retinopathy

作　　者：刘丹丹 徐国彤[1] 张敬法 Dan-Dan Liu;Guo-Tong Xu;Jing-Fa Zhang(Tongji University School of Medicine,Tongji Eye Institute,Shanghai 200092,China;Department of Ophthalmology,Shanghai General Hospital,Shanghai First People's Hospital,Shanghai 200080,China)

机构地区：[1]同济大学医学院同济眼科研究所,中国上海市200092 [2]上海交通大学附属第一人民医院眼科,中国上海市200080

出　　处：《国际眼科杂志》2021年第9期1539-1542,共4页International Eye Science

基　　金：国家自然科学基金面上项目(No.81570852)。

摘　　要：糖尿病性视网膜病变是糖尿病最常见和严重的眼部并发症,也是工作年龄人群致盲的主要原因。视网膜内几乎所有类型的细胞均受累及,导致视网膜“神经-血管单元”和“神经-胶质网络”破坏及功能障碍。促红细胞生成素(erythropoietin,EPO)是一种糖蛋白激素,研究发现EPO在多种中枢神经系统疾病中发挥神经保护、神经营养、抗炎、抗凋亡及抗氧化等作用。本文主要就EPO维持糖尿病性视网膜病变状态下视网膜的功能进行综述,以期为糖尿病性视网膜病变的临床治疗提供新思路。Diabetic retinopathy(DR)is the most common complication of diabetes mellitus and remains the leading cause of blindness in working-age population.DR affects almost all the retinal cells,leading to the disruption and dysfunction of neurovascular unit and the neural-glial network.Erythropoietin(EPO),a glycoprotein hormone,plays a pivotal role in neuroprotection,neurotrophy,anti-inflammation,anti-apoptosis and anti-oxidation etc.,in various central nervous system diseases.This review discussed the protective effect of EPO in DR so as to provide new options for DR treatment.

关 键 词：糖尿病性视网膜病变 促红细胞生成素 神经-血管单元 神经-胶质网络 

分 类 号：R58[医药卫生—内分泌]